BioCentury
ARTICLE | Clinical News

Thymitaq nolatrexed: Completed Phase III enrollment

April 25, 2005 7:00 AM UTC

Eximias completed enrollment of 446 patients in the open-label, international Phase III ETHECC trial. Thymitaq, which has Fast Track and Orphan designations, was licensed from Agouron Pharmaceuticals ...